J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports (updated)

Inari Medical

12/01/2025 22:26

(Adds details of possible bid, company and industry background,
paragraphs 2-6)
       Jan 12 (Reuters) - Drug maker Johnson & Johnson  JNJ.N 
is exploring a bid to acquire Intra-Cellular Therapies  ITCI.O ,
a biopharmaceutical company, Bloomberg News reported on Sunday,
citing people familiar with the matter.
    Intra-Cellular has a market value of about $10 billion,
according to LSEG data.
    Talks are still ongoing and a deal is not certain, the
report said, adding that other potential suitors could also
emerge. 
    J&J and Intra-Cellular Therapies did not immediately respond
to Reuters' requests for a comment. 
     Medical-device maker Stryker  SYK.N  had, on Monday, agreed
to acquire Inari Medical  NARI.O , which makes devices that
treat patients with venous diseases, in an all-cash deal worth
$4.9 billion.
    Healthcare is an active sector for M&A, with deals such as
Johnson & Johnson's acquisition of heart device business
Shockwave Medical for $13.1 billion announced in April, and
KKR's  KKR.N  acquisition of a stake in health tech firm
Cotiviti in February 2024.


 (Reporting by Angela Christy in Bengaluru
Editing by Sandra Maler and Matthew Lewis)
 ((AngelaChristy.M@thomsonreuters.com;))